Since its introduction in 2001, the independent director system has played an essential role in corporate governance. However, the Kangmei Pharmaceuticals case ruled that independent directors were liable for huge compensation totaling 369 million yuan within a specific range, leading to a rise in the resignation rate of independent directors. As an independent director, how do you assume responsibility in the face of false statement disputes? What kind of responsibility? What is the precise foundation and source of responsibility? In fact, the Judicial Interpretation of False Statements prior to the 2022 , because of the existence of a predicate proceeding for commencing a civil action, there have been very few cases in which independent directors have been held liable for civil liabilities, and when there have been cases, they have gone unnoticed because of the small amount of compensation for which they have been held liable.The China Securities Regulatory Commission and the State Council have successively issued The Rules for the Implementation of the System of Independent Directors of Listed Companies and the Opinions on the Reform of the System of Independent Directors of Listed Companies, which have been issued successively, are mostly aimed at safeguarding the interests of small and medium-sized investors.July 2023, the State Council introduced the Directors' Measures for the Administration of Independent Directors of Listed Companies. In December of the same year, the NPC Standing Committee passed the new Company Law,which also aims to protect the interests of small and medium investors,enhance the accountability of directors and regulators,and play a modest role in the institution of independent directors and their responsibilities. Based on an extensive survey of relevant overseas systems, independent directors play an essential role in corporate governance and can apply to proportional joint and liability. However, some challenges, such as unclear boundaries of responsibility, unclear standards of diligence and responsibility, and lack of responsibility reduction and remission mechanisms, aggravate the burden of responsibility of the five independent directors of Kangmei Pharmaceutical. In this regard, the optimization path is put forward, such as clarifying the responsibility boundary of independent directors, refining the recognition standard of diligence and responsibility, and constructing the corresponding responsibility reduction and remission mechanism. Strives to protect investor rights and interests, improve corporate governance, promote the growth of the capital market, and encourage the development of the independent director system.